FDA Purple Book · Reference family
tralokinumab-ldrm (Adbry)
tralokinumab-ldrm is an FDA-licensed reference biologic from LEO Pharma A/S. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
351(a)BLA 761180
Adbry tralokinumab-ldrm
LEO Pharma A/S
- Approved
- Jun 12, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for tralokinumab-ldrm, in chronological order.
Reference approval
Approval date of the reference tralokinumab-ldrm product.
2 yr ago
Frequently asked questions
Are there biosimilars approved for tralokinumab-ldrm (Adbry)?
No 351(k) biosimilars or interchangeable biosimilars referencing tralokinumab-ldrm are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.